Rossari Biotech Limited — Important, 25-04-2025: Capacity addition

The Board of Directors of Rossari Biotech Limited has approved several key resolutions during the recent board meeting. The company reported consolidated financial results for the quarter and financial year ending March 31, 2025, showing a substantial revenue from operations of ₹20,802.94 crore, up from ₹18,305.58 crore in the previous year. The profit after tax was recorded at ₹1,363.78 crore, demonstrating consistent growth compared to ₹1,306.89 crore last year.

Additionally, a final dividend of ₹0.50 per share has been proposed, which represents 25% of the face value. The Board also appointed M/s. Shah Patel & Associates as the secretarial auditor for a five-year term and approved the grant of stock options under the Rossari Employee Stock Option Plan - 2019, totaling 834,250 options. Furthermore, plans for a capacity addition of 13,000 MTPA were endorsed, requiring an investment of ₹95 crore, aimed to meet new product lines and market demand, with completion expected by FY 2025-26. This indicates a positive outlook for growth and strategic positioning within the specialty chemicals market.